<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37268601</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-0962</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Lupus</Title><ISOAbbreviation>Lupus</ISOAbbreviation></Journal><ArticleTitle>Diffuse alveolar haemorrhage in systemic lupus erythematosus: A multicentre retrospective study in Singapore.</ArticleTitle><Pagination><StartPage>952</StartPage><EndPage>963</EndPage><MedlinePgn>952-963</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09612033231180704</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Diffuse alveolar haemorrhage (DAH) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). We describe the clinical characteristics, treatment and survival outcomes of SLE patients with DAH in Singapore.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective review of the medical records of SLE patients with DAH hospitalised in 3 tertiary hospitals between January 2007 and October 2017. Patient demographics, clinical characteristics, laboratory, radiologic and bronchoscopic findings, as well as the treatments, were compared between survivors and non-survivors. Survival rates were analysed between the various treatment groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 35 patients with DAH were included in this study. Majority of them were female (71.4%) and of Chinese ethnicity (62.9%). Median age was 40.0&#xa0;years (IQR: 25-54), with a median disease duration of 8.9&#xa0;months (IQR: 0.13-102.4). Haemoptysis was the most common clinical presentation, and majority had concomitant cytopaenia and lupus nephritis. All patients received high dose glucocorticoids; 27 (77.1%), 16 (45.7%) and 23 (65.7%) received cyclophosphamide (CYP), rituximab (RTX), and plasmapheresis (PLEX), respectively. Twenty-two patients required mechanical ventilation with a median duration of 12&#xa0;days. Overall mortality rate was 40%, with a median survival time of 162 days. Twenty-six patients (74.3%) achieved remission, with an overall median time to remission of 12&#xa0;days (IQR: 6-46) after diagnosis of DAH. Patients on triple therapy (CYP, RTX and PLEX) had a median survival of 162&#xa0;days as compared to 14&#xa0;days in patients on PLEX alone (<i>p</i> = .0026).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The overall mortality of DAH in SLE patients remained high. There were no significant differences in patient demographics or clinical characteristics between the survivors and non-survivors. However, better survival appears to be associated with treatment with cyclophosphamide.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Law</LastName><ForeName>Annie Hn</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Singapore General Hospital, Singapore.</Affiliation><Identifier Source="RINGGOLD">37581</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Duke-NUS Medical School, Singapore.</Affiliation><Identifier Source="RINGGOLD">121579</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuah</LastName><ForeName>Tyng Yu</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Department of General Medicine (Rheumatology), Sengkang General Hospital, Singapore.</Affiliation><Identifier Source="RINGGOLD">541849</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Weixian</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medicine (Rheumatology), Ng Teng Fong General Hospital, Singapore.</Affiliation><Identifier Source="RINGGOLD">242949</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teng</LastName><ForeName>Gim Gee</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, National University Hospital, Singapore.</Affiliation><Identifier Source="RINGGOLD">37580</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation><Identifier Source="RINGGOLD">37580</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lian</LastName><ForeName>Tsui Yee</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore.</Affiliation><Identifier Source="RINGGOLD">63703</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saffari</LastName><ForeName>Seyed Ehsan</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Centre for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore.</Affiliation><Identifier Source="RINGGOLD">37580</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Li-Ching</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Singapore General Hospital, Singapore.</Affiliation><Identifier Source="RINGGOLD">37581</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Duke-NUS Medical School, Singapore.</Affiliation><Identifier Source="RINGGOLD">121579</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>Yong Loo Lin School of Medicine, National University of Singapore, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus</MedlineTA><NlmUniqueID>9204265</NlmUniqueID><ISSNLinking>0961-2033</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012846" MajorTopicYN="N" Type="Geographic">Singapore</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008171" MajorTopicYN="Y">Lung Diseases</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011650" MajorTopicYN="N">Pulmonary Alveoli</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asians</Keyword><Keyword MajorTopicYN="N">cyclophosphamide</Keyword><Keyword MajorTopicYN="N">haemosiderin-laden macrophages</Keyword><Keyword MajorTopicYN="N">plasmapheresis</Keyword><Keyword MajorTopicYN="N">pulmonary haemorrhage</Keyword><Keyword MajorTopicYN="N">rituximab</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>3</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>2</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37268601</ArticleId><ArticleId IdType="doi">10.1177/09612033231180704</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>